Johnson & Johnson: Update on U.S. Regulatory Review of Subcutaneous Amivantamab
December 18, 2024
December 18, 2024
NEW BRUNSWICK, New Jersey, Dec. 18 (TNSres) -- Johnson and Johnson issued the following news release:
RARITAN, N.J., December 16, 2024 - Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients with non-small cell lung cancer ( . . .
RARITAN, N.J., December 16, 2024 - Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients with non-small cell lung cancer ( . . .